Patent · US Active

Abiraterone prodrugs

US10792292B2 · kind B2 · utility

3Cited by

10References

30Claims

0Family size

Assignee

PROPELLA THERAPEUTICS, INC. · US

Inventors

Matthew J. SHARP · Apex, US
William R. Moore · Pittsboro, US

Key dates

Filing date	Mar 4, 2020
Grant date	Oct 6, 2020
Priority date	—
Expiry date	Mar 4, 2040

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P35/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Sustained-release abiraterone prodrug formulations, methods, and kits for parenteral administration to a subject having a sex hormone-dependent benign or malignant disorder such as prostate cancer, a syndrome due to androgen excess, and/or a syndrome due to glucocorticoid excess such as hypercortisolemia.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.